Bristol Myers’ Stock Decline in Response to Weak Guidance is a gift to investors
Bristol myers squibb on Thursday reported better-the-exposed Quarterly Results, but weak guidance for 2025 sent shares lower. Jim Cramer’s Faith in the Drugmaker is UnSHAKEN. Revenue in the fourth Quarter Rose 8% Year Over Year to $ 12.34 Billion, Well ahead of the $ 11.57 billion consensus, according to analysts’ Estimates Compiled by LSEG. Adjusted … Read more